Johnson & Johnson (NYSE:JNJ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started. Thank you, everybody who's here. It's not exactly the weather and climate environment, it's been a big challenge here. Chris Shibutani from the Gol ...

Johnson & Johnson (NYSE:JNJ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started. Thank you, everybody who's here. It's not exactly the weather and climate environment, it's been a big challenge here. Chris Shibutani from the Gol ...

Loading...Loading...During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below a ...

The integration of AI and healthcare is well underway.The human lifespan has increased dramatically since the start of the 17th century, from an average of just 30-40 years to over 70 years today. However, the next leap forward in longevity could be even more profound, driven by the transformative power of artificial intelligence (AI).AI has the potential to revolutionize healthcare and aging research, enabling scientists to uncover groundbreaking insights into the biological processes underlying aging and ...

Maintaining stability and security in investment portfolios is vital in an adverse macroeconomic environment. For instance, the current higher-for-longer interest rate environment coupled with other volatile macro elements may lead stocks into an unexpected and sudden downfall.Therefore, investors often seek out recession-proof stocks when escaping turbulent financial markets. These stocks have fundamentals that allow them to survive and flourish during difficult times — a fundamental and progressive resili ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $145.97, denoting a -1.24% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 1.19%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 1.96%.The the stock of world's biggest maker of health care products has fallen by 0.62% in the past month, lagging the Medical sector's gain of 3.54% and the S&P 500's gain of 3.35%.The investment community will ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental new drug application (sNDA) seeking expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States.Prezcobix is a two-drug fixed-dose combination tablet for treating HIV-1 infection in treatment-naïve and treatment-experienced adults and adolescent patients weighing at least 40 kg. It combines darunavir, J&J’s HIV-1 protease inhibitor, and cobicistat, Gilead Sciences’ (GILD) CYP3A inhibitor. J&J markets darunavir as ...

Johnson & Johnson (JNJ) announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder (MDD) with insomnia symptoms.The MDD3001 study evaluated the drug as an adjunctive treatment to baseline antidepressants in adult and elderly patients who did not benefit from antidepressants alone. The study met all its primary and secondary endpoints.Treatment with seltorexant achieved statistically signif ...

NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       ...

Johnson & Johnson (NYSE:JNJ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody. Welcome back from lunch. I'm Lee Hambright, US MedTech Analyst at Bernstein. And we are thrilled to host Johnson & Johnson's Chairman and CEO, Joaquin Duato. Thank you so much for being here. Joaquin Duato Thank you. Lee Hambright ...